ViaNautis Bio (formerly SomaServe) has raised $25 million (£20 million) in the recent Series A funding round. The investment was led by 4BIO Capital, BGF, and UCB Ventures with the participation of the Cystic Fibrosis Foundation, Eli Lilly and Company, and existing investors including Origin Capital, Meltwind, and O2H.
ViaNautis is a nanomedicine company working on genetic therapies. Its proprietary drug delivery platform, polyNaut®, is designed to deliver genetic therapeutic payloads across difficult-to-penetrate biological barriers, developing new medicines for diseases with unmet clinical needs. The company will use the new investment in the development of products using the polyNaut® platform, expand the scientific and management teams, and establish industry-leading lab facilities.
The company’s co-founders are Dr. Francesca Crawford, Dr. Denis Cecchin, and Professor Giuseppe Battaglia, who is the inventor of polyNaut® and an honorary professor at UCL, and it is headquartered in Cambridgeshire, England, United Kingdom.
Discover more from FundingBlogger
Subscribe to get the latest posts sent to your email.